Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.431 USD | -1.56% | +8.06% | +4.35% |
Apr. 04 | Transcript : VYNE Therapeutics Inc. - Special Call | |
Feb. 29 | VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 400K | Sales 2025 * | 250K | Capitalization | 34.82M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -40M | EV / Sales 2024 * | 87.1 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 139 x |
P/E ratio 2024 * |
-2.47
x | P/E ratio 2025 * |
-2.57
x | Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.31% |
Latest transcript on VYNE Therapeutics Inc.
1 day | -3.89% | ||
1 week | +7.39% | ||
Current month | -19.54% | ||
3 months | +38.76% | ||
6 months | +5.56% | ||
Current year | +6.01% |
Managers | Title | Age | Since |
---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 58 | 20-02-29 |
Tyler Zeronda
DFI | Director of Finance/CFO | 38 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 51 | 20-02-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pat LePore
BRD | Director/Board Member | 69 | 20-09-09 |
Steven Basta
BRD | Director/Board Member | 59 | 14-12-31 |
Anthony Bruno
BRD | Director/Board Member | 68 | 20-02-29 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.431 | -1.56% | 8 108 |
24-04-25 | 2.47 | -3.89% | 77,467 |
24-04-24 | 2.57 | +10.78% | 384,779 |
24-04-23 | 2.32 | -1.28% | 30,376 |
24-04-22 | 2.35 | +4.44% | 27,675 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.01% | 34.82M | |
+24.35% | 653B | |
+25.81% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+12.85% | 233B | |
+5.07% | 201B | |
-9.86% | 193B | |
-6.47% | 144B |
- Stock Market
- Equities
- VYNE Stock